Targeting ASK1 by CS17919 alleviates kidney- and liver-related diseases in murine models

Abstract

Background: Apoptosis signal-regulating kinase 1 (ASK1) is a MAP3K kinase in the MAPK signaling pathway activated by stressors and triggers downstream biological effects such as inflammation and apoptosis; therefore, inhibition of ASK1 kinase activity can protect cells from pathological injury. In this study, we designed and synthesized a novel selective ASK1 inhibitor, CS17919, and investigated its pharmacological effects in various animal models of metabolic injury.

Methods: First, we validated the ability of CS17919 to inhibit ASK1 in vitro and then tested the safety profile of CS17919 in cell lines compared with Selonsertib (GS-4997), a phase III ASK1 inhibitor. We then conducted pharmacokinetic (PK) studies in mice. Finally, we tested the in vivo efficacy of CS17919 in murine models of chronic kidney disease (CKD) and non-alcoholic steatohepatitis (NASH).

Results: Compared to GS-4997, CS17919 demonstrated comparable inhibition of ASK1 in vitro, exhibited lower toxicity, and provided greater protection in palmitic acid-treated LO2 cells. CS17919 also showed pronounced pharmacokinetic properties such as a high plasma concentration. In the unilateral ureteral obstruction model (UUO), CS17919 and GS-4997 preserved kidney function and showed a non-significant tendency to alleviate kidney fibrosis. In the diabetic kidney disease (DKD) model, CS17919 significantly improved serum creatinine and glomerular sclerosis. In the NASH model, the combination of CS17919 and a THRβ agonist (CS27109) was found to significantly improve liver inflammation and substantially reduced liver fibrosis.

Conclusions: CS17919 showed cell protective, anti-inflammatory, and antifibrotic effects in vitro and in vivo, suggesting its therapeutic potential for metabolic-related kidney and liver diseases.

Keywords

ASK1 ₁ / CKD ₄ / CS17919 ₂ / GS-4997 ₃ / NASH ₅

References

[1] Kim HJ, Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol. 2004;5:441-450.

[2] Sui X, Kong N, Ye L, et al. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2014;344:174-179.

[3] Okazaki T. ASK family in infection and inflammatory disease. Adv Biol Regul. 2017;66:37-45.

[4] Kojima K, Ichijo H, Naguro I. Molecular functions of ASK family in diseases caused by stress-induced inflammation and apoptosis. J Biochem. 2020;169:395-407.

[5] Tobiume K, Saitoh M, Ichijo H. Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol. 2002;191:95-104.

[6] Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997;275:90-94.

[7] Fujisawa T, Takeda K, Ichijo H. ASK family proteins in stress response and disease. Mol Biotechnol. 2007;37:13-18.

[8] Bachnoff N, Trus M, Atlas D. Alleviation of oxidative stress by potent and selective thioredoxin-mimetic peptides. Free Radic Biol Med. 2011;50:1355-1367.

[9] Shiizaki S, Naguro I, Ichijo H. Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. Adv Biol Regul. 2013;53:135-144.

[10] Wang Y, Wen H, Fu J, et al. Hepatocyte TNF receptor-associated factor 6 aggravates hepatic inflammation and fibrosis by promoting lysine 6-linked polyubiquitination of apoptosis signal-regulating kinase 1. Hepatology. 2020;71:93-111.

[11] Varga ZV, Giricz Z, Liaudet L, Haskó G, Ferdinandy P, Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta Mol Basis Dis. 1852;2015:232-242.

[12] Zhang X, Yang H, Zeng S, et al. Melanoma differentiation—associated gene 5 protects against NASH in mice. Hepatology. 2021;75:924-938.

[13] Challa TD, Wueest S, Lucchini FC, et al. Liver ASK1 protects from non-alcoholic fatty liver disease and fibrosis. EMBO Mol Med. 2019;11:e10124.

[14] Wang P-X, Ji Y-X. Zhang X, et al. Targeting P8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med. 2017;23:439-449.

[15] Gaul S, Geisler L, McGeough MD, et al. ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model. JCI Insight. 2020;5:e123294.

[16] Xiang M, Wang P-X. Wang A, et al. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. J Hepatol. 2016;64:1365-1377.

[17] Xie L, Wang P-X. Zhang P, et al. DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity. J Hepatol. 2016;65:113-124.

[18] Sharma M, Urano F, Jaeschke A. Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes. J Hepatol. 2012;56:192-198.

[19] Schuster S, Johnson CD, Hennebelle M, et al. Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice. J Lipid Res. 2018;59:1597-1609.

[20] Al-Lamki RS, Wang J, Vandenabeele P, et al. TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J. 2005;19:1637-1645.

[21] Ma F, Tesch GH, Nikolic-Paterson DJ. ASK1/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney. Am J Physiol Renal Physiol. 2014;307:F1263-F1273.

[22] Kretzler M. Role of podocytes in focal sclerosis: defining the point of No return. J Am Soc Nephrol. 2005;16:2830-2832.

[23] Li W, Cheng F, Songyang Y, Yang S, Wei J, Ruan Y. CTRP1 attenuates UUO-induced renal fibrosis via AMPK/NOX4 pathway in mice. Curr Med Sci. 2020;40:48-54.

[24] Degorce F, Card A, Soh S, Trinquet E, Knapik GP, Xie B. HTRF: a technology tailored for drug discovery -a review of theoretical aspects and recent applications. Curr Chem Genomics. 2009;3:22-32.

[25] Harrison SA, Wong VW-S. Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73:26-39.

[26] Lin JH, Zhang JJ, Lin S-L. Chertow GM. Design of a Phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2014;129:29-33.

[27] Ding J, Cui S, Li SY, et al. The angiotensin receptor neprilysin inhibitor LCZ696 attenuates renal fibrosis via ASK1/JNK/p38 MAPK-mediated apoptosis in unilateral ureteral obstruction. PLoS One. 2023;18:e0286903.

[28] Badal SS, Al Tuhaifi T, Yu Y-F. et al. Selonsertib enhances kidney protection beyond standard of care in a hypertensive, secondary glomerulosclerosis CKD model. Kidney360. 2022;3:1169-1182.

[29] Tesch GH, Ma FY, Nikolic-Paterson DJ. Targeting apoptosis signal-regulating kinase 1 in acute and chronic kidney disease. Anat Rec. 2020;303:2553-2560.

[30] Gregorini M, Sepe V, Pattonieri FE, Allesina A, Rampino T. Early onset of graft glomerulopathy in a patient with post-transplant diabetes mellitus after renal transplantation: a e report. BMC Nephrol. 2018;19:348.

[31] Tesch GH, Ma FY, Han Y, Liles JT, Breckenridge DG, Nikolic-Paterson DJ. ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-deficient mice. Diabetes. 2015;64:3903-3913.

[32] Liles JT, Corkey BK, Notte GT, et al. ASK1 contributes to fibrosis and dysfunction in models of kidney disease. J Clin Invest. 2018;128:4485-4500.

[33] Oe Y, Miyazaki M, Takahashi N. Coagulation, protease-activated receptors, and diabetic kidney disease: lessons from eNOS-deficient mice. Tohoku J Exp Med. 2021;255:1-8.

RIGHTS & PERMISSIONS

2024 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.